Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 (Olokizumab) Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056

NCT01296711 is registered in ClinicalTrials.gov with UCB BIOSCIENCES, Inc. as lead sponsor.

NCT NCT01296711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01296711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 (Olokizumab) Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Lead sponsor
UCB BIOSCIENCES, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 7, 2011
Completion date
August 5, 2013
Enrollment
190 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis